Protein
|
Fibril Origins
|
Residues Ordered
|
Method
|
Resol- ution (Å)
|
Polarity Map
|
Energy Map
|
PDB ID
|
Reference
|
α-synuclein
| Human, recombinant
| 43-83
| cryoEM
| 3.6
|  |
 |
6cu8
|
Li et al., 2018
|
α-synuclein
| Human, recombinant
| 43-97
| ssNMR
| N/A
|  |
 |
2n0a
|
Tuttle et al., 2016
|
α-synuclein
| Human, recombinant, seeded from Multiple System Atrophy Case 5, filament type 3
| 36-99
| cryoEM
| 3.18
|  |
 |
7nck
|
Lövestam et al., 2021
|
α-synuclein
| Human, H50Q mutant, recombinant
| 36-99
| cryoEM
| 3.3
|  |
 |
6peo
|
Boyer et al., 2019
|
α-synuclein
| Human, recombinant, pH 7.0, type 1m
| 13-20,36-100
| cryoEM
| 3.26
|  |
 |
8pk2
|
Frey et al., 2024
|
α-synuclein
| Human, mixture of wild type and MAAAEKT insertion mutation after residue 22, extracted from patient with Juvenile-Onset Synucleinopathy, singlet filament
| 14-25,36-100
| cryoEM
| 2.00
|  |
 |
8bqv
|
Yang et al., 2023
|
α-synuclein
| Human, mixture of wild type and MAAAEKT insertion mutation after residue 22, extracted from patient with Juvenile-Onset Synucleinopathy, doublet filament
| 14-25,36-100
| cryoEM
| 2.30
|  |
 |
8bqw
|
Yang et al., 2023
|
α-synuclein
| Human, H50Q mutant, recombinant
| 36-99
| cryoEM
| 3.6
|  |
 |
6pes
|
Boyer et al., 2019
|
α-synuclein
| Human, A53E mutant, recombinant
| 38-99
| cryoEM
| 3.38
|  |
 |
7uak
|
Sun et al., 2023
|
α-synuclein
| Human, A53T mutant, recombinant
| 37-99
| cryoEM
| 3.5
|  |
 |
6lrq
|
Sun et al., 2020
|
α-synuclein
| Human, A53T mutatnt, recombinant
| 37-100
| cryoEM
| 3.40
|  |
 |
7wnz
|
Huang et al., unpublished
|
α-synuclein
| human, recombinant, fold type 1B, induces oligodendroglial intracellular aggregates (GCIs)
| 37-97
| cryoEM
| 1.93
|  |
 |
9euu
|
Burger et al., 2024
|
α-synuclein
| Human, N-acetylated, 1-103, recombinant
| 37-96
| cryoEM
| 3.4
|  |
 |
6osm
|
Ni et al., 2019
|
α-synuclein
| Human, mixture of wild type and MAAAEKT insertion mutation after residue 22, recombinant, type 1 filament
| 37-99
| cryoEM
| 2.70
|  |
 |
8ce7
|
Yang et al., 2023
|
α-synuclein
| recombinant, human, heparin-remodeled
| 37-94
| cryoEM
| 3.50
|  |
 |
7v4d
|
Tao et al., 2022 unpublished
|
α-synuclein
| Human, recombinant, incubated with heparin for 3 days (Hep-remod-3)
| 37-94
| cryoEM
| 3.30
|  |
 |
8hzs
|
Tao, Zhao, Liu, 2023 unpublished
|
α-synuclein
| Human, mixture of wild type and MAAAEKT insertion mutation after residue 22, recombinant, type 2 filament
| 40-97
| cryoEM
| 2.70
|  |
 |
8ceb
|
Yang et al., 2023
|
α-synuclein
| recombinant, human, complex with ligand F0502B
| 37-97
| cryoEM
| 2.6
|  |
 |
7wmm
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, Thioflavin T ligand, conformation 1
| 37-97
| cryoEM
| 2.9
|  |
 |
7ynm
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, Thioflavin T ligand, conformation 2
| 37-97
| cryoEM
| 2.9
|  |
 |
7ynn
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, Pitssburgh compound B ligand, conformation 1
| 37-97
| cryoEM
| 2.8
|  |
 |
7yno
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, Pittsburgh compound B ligand, conformation 2
| 37-97
| cryoEM
| 2.8
|  |
 |
7ynq
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, BF227 ligand
| 37-97
| cryoEM
| 2.8
|  |
 |
7ynp
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, EB ligand
| 40-97
| cryoEM
| 2.6
|  |
 |
7ynl
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, Congo Red ligand (disordered)
| 37-99
| cryoEM
| 3.1
|  |
 |
7yng
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, C05-03 ligand (disordered)
| 37-97
| cryoEM
| 2.9
|  |
 |
7ynr
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, SIL5 ligand (disordered)
| 37-97
| cryoEM
| 3.0
|  |
 |
7yns
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, chondroitin
| 37-97
| cryoEM
| 3.00
|  |
 |
8zwi
|
Tao et al., 2024 unpublished
|
α-synuclein
| Human, recombinant, pFTAA ligand (disordered)
| 40-97
| cryoEM
| 3.1
|  |
 |
7ynt
|
Tao et al., 2023 unpublished
|
α-synuclein
| Human, recombinant, rod polymorph
| 38-97
| cryoEM
| 3.5
|  |
 |
6cu7
|
Li et al., 2018
|
α-synuclein
| Human, N-acetylated, 1-122, recombinant
| 39-97
| cryoEM
| 3.0
|  |
 |
6osl
|
Ni et al., 2019
|
α-synuclein
| Human, ΔN7, recombinant, in PBS buffer
| 42-92
| cryoEM
| 2.50
|  |
 |
8qpz
|
Dewison et al., 2024
|
α-synuclein
| Human, N-acetylated, 1-140, recombinant
| 37-97
| cryoEM
| 2.8
|  |
 |
6osj
|
Ni et al., 2019
|
α-synuclein
| Human, N-acetylated, 1-140, recombinant
| 37-99
| cryoEM
| 3.07
|  |
 |
6a6b
|
Li et al., 2018
|
α-synuclein
| Human, 1-121, recombinant
| 38-95
| cryoEM
| 3.4
|  |
 |
6h6b
|
Guerrero-Ferreira et al., 2018
|
α-synuclein
| Human, recombinant, polyadenylate, polymorph 2
| 37-99
| cryoEM
| 3.40
|  |
 |
8zwk
|
Tao et al., 2024 unpublished
|
α-synuclein
| Human, 1-140, recombinant, induced by ferric iron
| 37-99
| cryoEM
| 2.7
|  |
 |
7xjx
|
Zhao et al., 2023
|
α-synuclein
| Human, 1-140, non-acetylated, apo, recombinant
| 37-99
| cryoEM
| 2.8
|  |
 |
7yk2
|
Zhang et al., 2023
|
α-synuclein
| Human, recombinant, polyadenylate, polymorph 1
| 37-97
| cryoEM
| 3.10
|  |
 |
8zwj
|
Tao et al., 2024 unpublished
|
α-synuclein
| recombinant, human, polyphosphate
| 37-99
| cryoEM
| 3.10
|  |
 |
9ijp
|
Tao et al., 2024 unpublished
|
α-synuclein
| Human, wild type, N-acetylated, recombinant
| 39-94
| cryoEM
| 3.10
|  |
 |
8oqi
|
Pesch et al., 2024
|
α-synuclein
| Human, 1-140, non-acetylated, recombinant, with dLAG3 receptor
| 14-25,37-99
| cryoEM
| 2.8
|  |
 |
7yk8
|
Zhang et al., 2023
|
α-synuclein
| Human, recombinant, incubated with heparin for 1 hour (Hep-remod-2)
| 14-22,37-99
| cryoEM
| 3.20
|  |
 |
8hzb
|
Tao, Zhao, Liu, 2023 unpublished
|
α-synuclein
| Human, recombinant, incubated with heparin for 1 hour (Hep-remod-2)
| 14-25,37-99
| cryoEM
| 3.20
|  |
 |
8hzc
|
Tao, Zhao, Liu, 2023 unpublished
|
α-synuclein
| Human, recombinant
| 15-22,36-97
| cryoEM
| 2.04
|  |
 |
9ck3
|
Sanchez et al., 2024 unpublished
|
α-synuclein
| Human, recombinant, from liquid-liquid phase separation, late fibrils
| 38-97
| cryoEM
| 3.30
|  |
 |
8ri9
|
Chen et al., 2024
|
α-synuclein
| human, recombinant
| 37-96
| cryoEM
| 3.20
|  |
 |
8rqm
|
Monistrol et al., 2024 Biorxiv
|
α-synuclein
| human, recombinant, seeded from a Parkinson's Disease patient, postmortem, filament type 4
| 36-95
| cryoEM
| 3.40
|  |
 |
7v49
|
Fan et al., 2023
|
α-synuclein
| recombinant, human, seeded from a Parkinson's Disease patient, postmortem, minor polymorph
| 36-95
| cryoEM
| 3.40
|  |
 |
8h05
|
Fan et al., 2023
|
α-synuclein
| human, extracted from Multiple System Atrophy Case 2, Type II-2 fibril
| 14-99
| cryoEM
| 3.1
|  |
 |
6xyq
|
Schweighauser et al., 2020
|
α-synuclein
| human, extracted from Multiple System Atrophy brain, Case 2, Type II-1 fibril
| 14-99
| cryoEM
| 3.3
|  |
 |
6xyp
|
Schweighauser et al., 2020
|
α-synuclein
| human, extracted from Multiple System Atrophy brain, Case 2, Type II-1 fibril
| 14-99
| cryoEM
| 3.2
|  |
 |
9cx6
|
Yang et al., 2024 unpublished
|
α-synuclein
| human, extracted from Multiple System Atrophy brain, Case 1, Type I fibril
| 14-99
| cryoEM
| 2.6
|  |
 |
6xyo
|
Schweighauser et al., 2020
|
α-synuclein
| Human, E46K mutant, recombinant
| 45-99
| cryoEM
| 3.37
|  |
 |
6l4s
|
Zhao et al., 2020a
|
α-synuclein
| Human, E46K mutant, recombinant, heparin
| 45-99
| cryoEM
| 2.50
|  |
 |
8zwh
|
Tao et al., 2024 unpublished
|
α-synuclein
| Human, wild type, recombinant, seeded with E46K mutant
| 46-96
| cryoEM
| 3.8
|  |
 |
7c1d
|
Long et al., 2021
|
α-synuclein
| Human, G51D mutation, recombinant
| 50-98
| cryoEM
| 3.02
|  |
 |
7e0f
|
Sun et al., 2021
|
α-synuclein
| Human, recombinant, recombinant, heparin-induced, polymorph 4
| 37-98
| cryoEM
| 3.30
|  |
 |
7v4c
|
Tao et al., 2022
|
α-synuclein
| Human, recombinant, recombinant, heparin-induced, polymorph 1
| 14-25, 32-99
| cryoEM
| 3.20
|  |
 |
7v4a
|
Tao et al., 2022
|
α-synuclein
| Human, recombinant, polymorph 2b
| 14-25, 36-96
| cryoEM
| 3.4
|  |
 |
6sst
|
Guerrero-Ferreira et al., 2019
|
α-synuclein
| Human, recombinant, polymorph 2b
| 9-24, 35-93
| cryoEM
| 3.5
|  |
 |
6rtb
|
Guerrero-Ferreira et al., 2019
|
α-synuclein
| Human, recombinant, seeded from Multiple System Atrophy Case 2, fold A, doublet type 2
| 37-97
| cryoEM
| 3.43
|  |
 |
7ncg
|
Lövestam et al., 2021
|
α-synuclein
| Human, recombinant, seeded from Multiple System Atrophy Case 1, fold B, doublet type 2
| 14-25, 36-91
| cryoEM
| 3.55
|  |
 |
7nci
|
Lövestam et al., 2021
|
α-synuclein
| Human, recombinant, seeded from Multiple System Atrophy Case 1, folds A and B, doublet type 2
| 37-97
| cryoEM
| 4.23
|  |
 |
7ncj
|
Lövestam et al., 2021
|
α-synuclein
| Human, recombinant, pH 5.8, type 3B
| 35-98
| cryoEM
| 2.42
|  |
 |
9fyp
|
Frey et al., 2024
|
α-synuclein
| recombinant, seeded from Multiple System Atrophy
| 36-93
| cryoEM
| 3.02
|  |
 |
7ozh
|
Frieg et al., 2022
|
α-synuclein
| recombinant, human, seeded from a Parkinson's Disease patient, mid-to-late stage 1, major polymorph
| 36-97
| cryoEM
| 3.00
|  |
 |
7xo1
|
Fan et al., 2023
|
α-synuclein
| recombinant, human, seeded from a Parkinson's Disease patient, mid-to-late stage 4, filament type 1C
| 36-98
| cryoEM
| 2.60
|  |
 |
7xo3
|
Fan et al., 2023
|
α-synuclein
| recombinant, human, seeded from a Parkinson's Disease patient, preclinical, filament type 1A
| 36-96
| cryoEM
| 2.80
|  |
 |
7v47
|
Fan et al., 2023
|
α-synuclein
| recombinant, human, seeded from Parkinson's Disease patient, preclinical, major polymorph
| 36-96
| cryoEM
| 2.80
|  |
 |
8h03
|
Fan et al., 2023
|
α-synuclein
| recombinant, human, seeded from a Parkinson's Disease patient, postmortem, filament type 1D
| 36-98
| cryoEM
| 3.00
|  |
 |
7v48
|
Fan et al., 2023
|
α-synuclein
| recombinant, human, seeded from a Parkinson's Disease patient postmortem, major polymorph
| 36-98
| cryoEM
| 3.00
|  |
 |
8h04
|
Fan et al., 2023
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 3, Fibril Class 2b, compact pore, type 1 warp
| 14-25,36-96
| cryoEM
| 3.10
|  |
 |
8cyw
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| Human, recombinant, spontaneous control
| 15-24,36-97
| cryoEM
| 4.20
|  |
 |
8cyr
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 1, Fibril Class 2b, extended pore, type 2 warp
| 15-24,36-97
| cryoEM
| 3.10
|  |
 |
8cys
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 2, Fibril Class 2b, extended pore, type 1 & 2 warp
| 15-24,36-97
| cryoEM
| 3.50
|  |
 |
8cyv
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 5, Fibril Class 2b, extended pore, type 1 & 2 warps
| 15-24,36-97
| cryoEM
| 3.10
|  |
 |
8cyy
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 7, Fibril Class 2b, extended pore, type 1 warp
| 15-24,36-97
| cryoEM
| 2.90
|  |
 |
8cz0
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 7, Fibril Class 2b, extended pore, type 2 warp
| 15-24,36-97
| cryoEM
| 3.00
|  |
 |
8cz1
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 10, Fibril Class 2b, extended pore, type 1 warp
| 15-24,36-97
| cryoEM
| 3.20
|  |
 |
8cz3
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| recombinant, human, recombinant, heparin-induced, polymorph 3
| 14-25, 32-99
| cryoEM
| 3.10
|  |
 |
7v4b
|
Tao et al., 2022
|
α-synuclein
| Human, A53T mutant, recombinant
| 35-99
| cryoEM
| 2.70
|  |
 |
7wo0
|
Huang et al., unpublished
|
α-synuclein
| Human, recombinant, pH 5.8, type 3D
| 36-98
| cryoEM
| 2.31
|  |
 |
8pjo
|
Frey et al., 2024
|
α-synuclein
| Human, recombinant, polymorph 2a
| 14-25, 36-95
| cryoEM
| 3.1
|  |
 |
6rt0
|
Guerrero-Ferreira et al., 2019
|
α-synuclein
|
Human, recombinant, polymorph 2a
|
14-25, 36-96
|
cryoEM
|
3.0
|
 |
 |
6ssx
|
Guerrero-Ferreira et al., 2019
|
α-synuclein
|
Human, E46K mutant, recombinant
|
36-98
|
cryoEM
|
2.5
|
 |
 |
6ufr
|
Boyer et al., 2020
|
α-synuclein
| Human, recombinant, pH 5.8, type 3C
| 33-97
| cryoEM
| 3.41
|  |
 |
8pix
|
Frey et al., 2024
|
α-synuclein
| Human, recombinant, seeded from Multiple System Atrophy Case 2, fold A, doublet type 1
| 37-97
| cryoEM
| 3.47
|  |
 |
7nca
|
Lövestam et al., 2021
|
α-synuclein
| recombinant, human, seeded from a Parkinson's Disease patient, mid-to-late stage 1, minor polymorph
| 36-97
| cryoEM
| 3.00
|  |
 |
7xo0
|
Fan et al., 2023
|
α-synuclein
| recombinant, human, seeded from a Parkinson's Disease patient, mid-to-late stage 4, minor polymorph
| 36-97
| cryoEM
| 3.00
|  |
 |
7xo2
|
Fan et al., 2023
|
α-synuclein
| recombinant, seeded from Multiple System Atrophy Case 1, fold B, doublet type 1
| 14-25, 36-91
| cryoEM
| 3.84
|  |
 |
7nch
|
Lövestam et al., 2021
|
α-synuclein
| recombinant, seeded from brain of Parkinson's Disease Patient
| 14-25,36-96
| cryoEM
| 3.30
|  |
 |
7ozg
|
Frieg et al., 2022
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 3, Fibril Class 2a, compact pore, type 1 warp
| 14-25,36-96
| cryoEM
| 3.00
|  |
 |
8cyx
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 1, Fibril Class 2a, extended pore, type 1 warp
| 15-24,36-97
| cryoEM
| 3.00
|  |
 |
8cyt
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 7, Fibril Class 2a, extended pore, type 1 warp
| 15-24,36-97
| cryoEM
| 3.00
|  |
 |
8cz2
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| Human, recombinant, seeded from Dementia with Lewy Bodies Case 10, Fibril Class 2a, extended pore, type 1 warp
| 15-24,36-97
| cryoEM
| 3.20
|  |
 |
8cz6
|
Sokratian et al., 2023 BioRxiv
|
α-synuclein
| human, recombinant
| 14-25,36-97
| cryoEM
| 3.40
|  |
 |
8rrr
|
Monistrol et al., 2024 Biorxiv
|
α-synuclein
| Human, recombinant, Lipidic, Polymorph L2B
| 14-24,33-96
| cryoEM
| 3.05
|  |
 |
8ads
|
Frieg et al., 2022b
|
α-synuclein
| Human, recombinant, Lipidic, Polymorph L3A
| 14-19,33-97
| cryoEM
| 2.76
|  |
 |
8aex
|
Frieg et al., 2022b
|
α-synuclein
| Human, recombinant, pH 7.0, type 5A
| 2-96
| cryoEM
| 3.30
|  |
 |
8pk4
|
Frey et al., 2024
|
α-synuclein
| Human, recombinant, Lipidic, Polymorph L1A
| 1-99
| cryoEM
| 3.24
|  |
 |
8adu
|
Frieg et al., 2022b
|
α-synuclein
| Human, recombinant, Lipidic, Polymorph L1B
| 1-99
| cryoEM
| 2.98
|  |
 |
8adv
|
Frieg et al., 2022b
|
α-synuclein
| Human, recombinant, Lipidic, Polymorph L1C
| 1-99
| cryoEM
| 2.95
|  |
 |
8adw
|
Frieg et al., 2022b
|
α-synuclein
| human, recombinant, heparin-remodeled, lipidic polymorph L2A
| 14-24, 33-96
| cryoEM
| 3.22
|  |
 |
8a4l
|
Frieg et al., 2022
|
α-synuclein
| human, extracted from Parkinson's Disease Dementia patient brain; identical fold as Parkinson's Disease and Dementia with Lewy bodies
| 14-22, 31-100
| cryoEM
| 2.16
|  |
 |
8a9l
|
Yang et al., 2022
|
α-synuclein
| human, recombinant, seeded with fibrils from a patient with Dementia with Lewy bodies
| 30-103
| ssNMR
| N/A
|  |
 |
8fpt
|
Dhavale et al., 2023
|
α-synuclein
| Human, phospho-Y39, semisynthetic, twist-dimer
| 1-100
| cryoEM
| 3.22
|  |
 |
6l1t
|
Zhao et al., 2020b
|
α-synuclein
| Human, phospho-Y39, semisynthetic, twist-dimer
| 1-100
| cryoEM
| 3.37
|  |
 |
6l1u
|
Zhao et al., 2020b
|
α-synuclein
| Human, 41-140, recombinant
| 46-96
| cryoEM
| 3.20
|  |
 |
7lc9
|
McGlinchey et al., 2021
|
α-synuclein
| Human, Ser87-O-GlcNAc Post-translational modification, synthetic
| 1-96
| cryoEM
| 4.80
|  |
 |
8gf7
|
Balana et al., 2024
|
α-synuclein
| Human, recombinant, filaments formed in the presence of Tau
| 37-79
| cryoEM
| 4.00
|  |
 |
7l7h
|
Hojjatian et al., 2021
|
Amyloid-β(1-42)
| recombinant
| 17-42
| ssNMR
| N/A
|  |
 |
2beg
|
Lührs et al., 2005
|
Amyloid-β(1-40) Iowa Mutation D23N
| recombinant
| 15-40
| ssNMR
| N/A
|  |
 |
2lnq
|
Qiang et al., 2012
|
Amyloid-β(1-40) (+)stagger
| recombinant
| 9-40
| ssNMR
| N/A
|  |
 |
2lmn
|
Paravastu et al., 2008
|
Amyloid-β(1-40) (-)stagger
| recombinant
| 9-40
| ssNMR
| N/A
|  |
 |
2lmo
|
Paravastu et al., 2008
|
Amyloid-β(1-40)
| recombinant
| 11-40
| ssNMR
| N/A
|  |
 |
6ti5
|
Cerofolini et al., 2020
|
Amyloid-β(1-40 and 1-42 co-fibril)
| human, recombinant
| 11-40, 11-42
| ssNMR
| N/A
|  |
 |
6ti6
|
Cerofolini et al., 2020
|
Amyloid-β(1-40) (+)stagger
| recombinant
| 9-40
| ssNMR
| N/A
|  |
 |
2lmp
|
Paravastu et al., 2008
|
Amyloid-β(1-40) (-)stagger
| recombinant
| 9-40
| ssNMR
| N/A
|  |
 |
2lmq
|
Paravastu et al., 2008
|
Amyloid-β(1-40) Iowa Mutation D23N
| recombinant
| 15-40
| ssNMR
| N/A
|  |
 |
2mpz
|
Sgourakis et al., 2015
|
Amyloid-β(1-40)
| recombinant, seeded from brain of a human with Alzheimers Disease
| 1-40
| ssNMR
| N/A
|  |
 |
2m4j
|
Lu et al., 2013
|
Amyloid-β(1-42)
| recombinant
| 16-40
| CryoEM
| 5.0
|  |
 |
5aef
|
Schmidt et al., 2015
|
Amyloid-β(1-42)
| recombinant, seeded from the brain of a human with Alzheimers Disease, type B fibril
| 1-42
| CryoEM
| 2.76
|  |
 |
8eze
|
Lee et al., 2023
|
Amyloid-β(1-40)
| Seeded with fibrils extracted from brain of a human with Alzheimers Disease (cortical tissue)
| 10-40
| cryoEM
| 2.77
|  |
 |
6w0o
|
Ghosh et al., 2021
|
Amyloid-β
| recombinant, unseeded, morphology i
| 13-40
| cryoEM
| 2.59
|  |
 |
8ot1
|
Pfeiffer et al., 2023
|
Amyloid-β
| recombinant, unseeded, morphology ii
| 13-40
| cryoEM
| 2.73
|  |
 |
8ot3
|
Pfeiffer et al., 2023
|
Amyloid-β
| Human, segment 1-40, recombinant, grown in lipidic vesicles, L1 fold
| 1-40
| cryoEM
| 2.88
|  |
 |
8ovk
|
Freig et al., 2024
|
Amyloid-β
| Extracted from brain of a human with Alzheimers Disease (meningeal tissue)
| 1-40
| cryoEM
| 4.4
|  |
 |
6shs
|
Kollmer et al., 2019
|
Amyloid-β
| recombinant, seeded with meningeal tissue of Alzheimer's patients, morphology I
| 1-37
| cryoEM
| 2.59
|  |
 |
8ot4
|
Pfeiffer et al., 2023
|
Amyloid-β(1-40)
| Human, extracted from individuals with Alzheimers Disease and Cerebral Amyloid Angiopathy (leptomeninges), doublet filament
| 1-38
| cryoEM
| 2.70
|  |
 |
8qn7
|
Yang et al., 2024
|
Amyloid-β(1-40)
| Human, extracted from individuals with Alzheimers Disease and Cerebral Amyloid Angiopathy (leptomeninges), quadruplet filament
| 1-38
| cryoEM
| 2.40
|  |
 |
8qn6
|
Yang et al., 2024
|
Amyloid-β(20-34)
| Synthetic
| 20-34
| MicroED
| 1.10
|  |
 |
6oiz
|
Warmack et al., 2019
|
Amyloid-β(20-34)(L-isoAsp23)
| Synthetic
| 20-34
| MicroED
| 1.10
|  |
 |
6nb9
|
Warmack et al., 2019
|
Amyloid-β(1-42) E22G
| Human, extracted from AppNL-G-F familial AD mouse model brain
| 1-38
| CryoEM
| 3.0
|  |
 |
8bfa
|
Leistner et al., 2023
|
Amyloid-β(1-42) E22G
| Human, extracted from AppNL-G-F familial AD mouse model brain, and stained with methoxy-X04
| 1-38
| CryoEM
| 3.2
|  |
 |
8bfb
|
Leistner et al., 2023
|
Amyloid-β(1-42)
| recombinant, seeded from the brain of a human with Alzheimers Disease, type A fibril
| 12-42
| CryoEM
| 2.83
|  |
 |
8ezd
|
Lee et al., 2023
|
Amyloid-β
| Human, E22G & D23N mutations, extracted from brain of transgenic mouse tg-SwDI, DI3 polymorph
| 2-33
| cryoEM
| 4.00
|  |
 |
8olq
|
Zielinski et al., 2023
|
Amyloid-β
| Human, E22G & D23N mutations, extracted from brain of transgenic mouse tg-SwDI, DI2 polymorph
| 1-39
| cryoEM
| 4.20
|  |
 |
8olg
|
Zielinski et al., 2023
|
Amyloid-β
| Human, E22G & D23N mutations, extracted from brain of transgenic mouse tg-SwDI, DI1 polymorph
| 1-36
| cryoEM
| 3.30
|  |
 |
8oln
|
Zielinski et al., 2023
|
Amyloid-β(1-42)
| recombinant
| 11-42
| ssNMR
| N/A
|  |
 |
2mxu
|
Xiao et al., 2015
|
Amyloid-β(1-42)
| recombinant
| 14-42
| ssNMR
| N/A
|  |
 |
5kk3
|
Colvin et al., 2016
|
Amyloid-β(1-42)
| recombinant
| 14-42
| ssNMR
| N/A
|  |
 |
2nao
|
Wälti et al., 2016
|
Amyloid-β(1-42), human
| Extracted from the brain of a patient with Alzheimers Disease, type I filament
| 9-42
| cryoEM
| 2.5
|  |
 |
7q4b
|
Yang et al., 2022
|
Amyloid-β(1-42), human
| Aqueous extracts from the brain of a patient with Alzheimers Disease, type I filament
| 9-42
| cryoEM
| 2.9
|  |
 |
8azs
|
Stern et al., 2023
|
Amyloid-β
| Human, segment 1-42, extracted from an individual with Down Syndrome and Alzheimers Disease, type I filament
| 9-42
| cryoEM
| 3.17
|  |
 |
8sej
|
Fernandez et al., 2024
|
Amyloid-β
| Human, segment 1-42, extracted from brain, type I filament
| 9-42
| cryoEM
| 3.30
|  |
 |
8kew
|
Zhao et al., unpublished 2024
|
Amyloid-β
| Human, segment 1-42, extracted from brain, AD case 2, type I filament
| 9-42
| cryoEM
| 3.00
|  |
 |
8kf4
|
Zhao et al., unpublished 2024
|
Amyloid-β
| Human, segment 1-42, extracted from brain, AD case 3, type I filament
| 9-42
| cryoEM
| 3.40
|  |
 |
8kf5
|
Zhao et al., unpublished 2024
|
Amyloid-β
| Human, segment 1-42, extracted from brain, type I filament, AV-45 bound
| 9-42
| cryoEM
| 3.30
|  |
 |
8kf1
|
Zhao et al., unpublished 2024
|
Amyloid-β
| Human, E22G mutation, extracted from brain of transgenic mouse tg-APPSwe, type I-like filament
| 9-40
| cryoEM
| 3.00
|  |
 |
8ol7
|
Zielinski et al., 2023
|
Amyloid-β
| Human, segment 1-42, extracted from brain, type I-ish and type II-ish filaments
| 9-42
| cryoEM
| 3.50
|  |
 |
8kf3
|
Zhao et al., unpublished 2024
|
Amyloid-β
| Human, segment 1-42, extracted from brain, type I-ish and type II-ish filaments, AV-45
| 9-42
| cryoEM
| 3.70
|  |
 |
8kf6
|
Zhao et al., unpublished 2024
|
Amyloid-β(1-42), human
| Extracted from the brain of a patient with Alzheimers Disease, type II filament
| 12-42
| cryoEM
| 2.8
|  |
 |
7q4m
|
Yang et al., 2022
|
Amyloid-β(1-42)
| Human, aqueous extracts from the brain of a patient with Alzheimers Disease, type II filament
| 12-42
| cryoEM
| 3.70
|  |
 |
8azt
|
Stern et al., 2023
|
Amyloid-β
| Human, extracted from an individual with Amyltrophic Lateral Sclerosis/Parkinsonism-dementia complex (ALS/PDC), Guam case 2, type-II filament
| 12-42
| cryoEM
| 3.30
|  |
 |
8otf
|
Qi et al., 2023
|
Amyloid-β(1-42)
| Human, Extracted from brain of transgenic mouse APP23, type II filament
| 12-42
| cryoEM
| 3.00
|  |
 |
8ol2
|
Zielinski et al., 2023
|
Amyloid-β(1-42)
| Human, Extracted from brain of transgenic mouse ARTE10, type II filament
| 12-42
| cryoEM
| 3.40
|  |
 |
8ol5
|
Zielinski et al., 2023
|
Amyloid-β(1-42)
| Human, Extracted from brain of transgenic mouse tg-APPSwe, type II filament
| 12-42
| cryoEM
| 3.80
|  |
 |
8ol6
|
Zielinski et al., 2023
|
Amyloid-β(1-42) E22G arctic mutation, human
| Extracted from the brain of a patient with Alzheimers Disease
| 12-42
| cryoEM
| 2.8
|  |
 |
8bfz
|
Yang et al., 2023
|
Amyloid-β(1-40) E22G arctic mutation, human
| Extracted from the brain of a patient with Alzheimers Disease
| 11-40
| cryoEM
| 1.99
|  |
 |
8bg0
|
Yang et al., 2023
|
Amyloid-β
| Human, segment 1-40, extracted from an individual with Down Syndrome and Alzheimers Disease, type IIIa filament
| 9-40
| cryoEM
| 3.50
|  |
 |
8sek
|
Fernandez et al., 2024
|
Amyloid-β
| Human, segment 1-40, extracted from an individual with Down Syndrome and Alzheimers Disease, type IIIb filament
| 1-40
| cryoEM
| 3.80
|  |
 |
8sel
|
Fernandez et al., 2024
|
Amyloid-β(1-42)
| Human, Extracted from brain of transgenic mouse APP/PS1, type III filament
| 10-42
| cryoEM
| 3.50
|  |
 |
8ol3
|
Zielinski et al., 2023
|
Amyloid-β(1-42)
| Human, Extracted from brain of transgenic mouse ARTE10, type III filament
| 10-40
| cryoEM
| 3.50
|  |
 |
8olo
|
Zielinski et al., 2023
|
Amyloid-β(1-42)
| Synthetic, glycosylated at Tyr10
| 6-42
| cryoEM
| 3.10
|  |
 |
7f29
|
Liu et al., 2021
|
Amyloid-β(1-40) E22G arctic mutation, human protein in mouse model
| Extracted from the brain of a mouse with Alzheimers Disease
| 1-37
| cryoEM
| 3.50
|  |
 |
8bg9
|
Yang et al., 2023
|
Amyloid-β(1-40) E22Δ Osaka mutation
| recombinant
| 1-40
| ssNMR
| N/A
|  |
 |
2mvx
|
Schütz et al., 2015
|
Amyloid-β(1-42)
| Human, recombinant
| 1-42
| cryoEM
| 4.0
|  |
 |
5oqv
|
Gremer et al., 2017
|
Amyloid-β
| Human, segment 1-40, recombinant, grown in lipidic vesicles, L2 fold
| 5-40
| cryoEM
| 3.24
|  |
 |
8ovm
|
Freig et al., 2024
|
Amyloid-β
| Human, segment 1-40, recombinant, grown in lipidic vesicles, L2 fold doublet
| 5-40
| cryoEM
| 3.75
|  |
 |
8owj
|
Freig et al., 2024
|
Amyloid-β
| Human, segment 1-40, recombinant, grown in lipidic vesicles, L3 fold
| 1-40
| cryoEM
| 3.28
|  |
 |
8owd
|
Freig et al., 2024
|
Amyloid-β
| Human, segment 1-40, recombinant, grown in lipidic vesicles, L3 fold doublet
| 1-40
| cryoEM
| 3.86
|  |
 |
8owk
|
Freig et al., 2024
|
Amyloid-β
| Human, segment 1-40, recombinant, grown in lipidic vesicles, L2 and L3 folds
| 1-40
| cryoEM
| 3.75
|  |
 |
8owe
|
Freig et al., 2024
|
Antimicrobial peptide uperin 3.5
| Mjobergs toadlet, synthetic
| 1-17
| cryoEM
| 3.0
|  |
 |
7qv5
|
Bücker et al., 2022
|
Antimicrobial peptide aurein 3.3
| Blue-thighed tree frog, synthetic
| 1-17
| cryoEM
| 3.5
|  |
 |
7qv6
|
Bücker et al., 2022
|
Apolipoprotein A-II
| Mouse, extracted from liver, fibril morphology I
| 4-71
| cryoEM
| 2.40
|  |
 |
8oq5
|
Andreotti et al., 2024
|
Apolipoprotein A-II
| Mouse, extracted from liver, fibril morphology II
| 4-71
| cryoEM
| 2.60
|  |
 |
8oq4
|
Andreotti et al., 2024
|
β-2-microglobulin
| recombinant
| 22-85
| cryoEM
| 3.9
|  |
 |
6gk3
|
Iadanza et al., 2018
|
β-2-microglobulin
| recombinant, fibril form 4PF
| 21-84
| cryoEM
| 2.8
|  |
 |
8a7q
|
Wilkinson et al., 2023
|
β-2-microglobulin D76N mutation
| recombinant, fibril form 2PFa
| 6-90
| cryoEM
| 3.0
|  |
 |
8a7t
|
Wilkinson et al., 2023
|
β-2-microglobulin ΔN6 mutation
| recombinant, fibril form 2PFa
| 6-93
| cryoEM
| 3.0
|  |
 |
8a7o
|
Wilkinson et al., 2023
|
β-2-microglobulin ΔN6 mutation
| recombinant, fibril form 2PFb
| 6-92
| cryoEM
| 3.4
|  |
 |
8a7p
|
Wilkinson et al., 2023
|
β-2-microglobulin
|
recombinant
|
20-41
|
ssNMR
|
N/A
|
 |
 |
2e8d
|
Iwata et al., 2006
|
β-endorphin
|
recombinant
|
1-31
|
ssNMR
|
N/A
|
 |
 |
6tub
|
Seuring et al., 2020
|
CA150 WW2 Domain
| recombinant
| 3-33
| ssNMR
| N/A
|  |
 |
2nnt
|
Ferguson et al., 2006
|
CsgA
| Pontibacteri korlensis, recombinant, major Curli subunit protein
| 1-355
| cryoEM
| 7.60
|  |
 |
8c50
|
Sleutel et al., 2023
|
CsgA
| Escherichia coli, in vitro, major Curli subunit protein
| 41-151
| cryoEM
| 3.62
|  |
 |
8enq
|
Bu et al., 2024
|
CPEB3
| segment 1-217, human, recombinant
| 2-50
| cryoEM
| 3.00
|  |
 |
8spa
|
Flores et al., 2022
|
De novo, Pyrene IDP
| Synthetic, intrinsically disordered short peptide forms fibrils, pH 2.0
| 1-6
| cryoEM
| 3.10
|  |
 |
7uuq
|
Guo et al., 2023
|
De novo, Pyrene IDP
| Synthetic, intrinsically disordered short peptide forms fibrils, pH 4.0, 2mM Ca2+
| 1-6
| cryoEM
| 3.00
|  |
 |
8gi5
|
Guo et al., 2023
|
De novo, Nitrobenzoxadiazole-ffsy D-peptide
| Synthetic, class 2 fibril, induces cells to form spheroids
| 1-5
| cryoEM
| 3.20
|  |
 |
8dst
|
Guo et al., 2023
|
De novo, Nitrobenzoxadiazole-ffsy D-peptide
| Synthetic, class 1 fibril, induces cells to form spheroids
| 1-5
| cryoEM
| 3.10
|  |
 |
7t6e
|
Guo et al., 2023
|
De novo, Biphenyl-4-peptidyl-ffsy D-peptide
| Synthetic, induces cells to form spheroids
| 1-5
| cryoEM
| 2.60
|  |
 |
8fof
|
Guo et al., 2023
|
De novo, RNA-binding amyloid peptide, C-terminally amidated, synthetic, with RNA
| Synthetic
| 1-8
| ssNMR
| N/A
|  |
 |
8pxs
|
Rout et al., 2023
|
De novo, catalytic Amyloid Fibril, Ac-LHLHLRL-NH2, p-nitrophenyl hydrolase
| Synthetic
| 1-7
| cryoEM
| 3.80
|  |
 |
8b3a
|
Heerde et al., 2023
|
De novo, Virus Enhancing Amyloid Fibril, PNF-18, CKFKFQF
| Synthetic
| 1-7
| cryoEM
| 2.86
|  |
 |
8okr
|
Heerde et al., 2023
|
De novo, Enzyme-cleaved Amyloid Peptide (EAP2), abeta-2, GPLGMLGGVVIA, polymorph 1
| Synthetic
| 1-12
| cryoEM
| 2.35
|  |
 |
8gz8
|
Wang et al., 2023
|
De novo, Enzyme-cleaved Amyloid Peptide (EAP2), abeta-2, GPLGMLGGVVIA, polymorph 2
| Synthetic
| 1-12
| cryoEM
| 2.62
|  |
 |
8gz9
|
Wang et al., 2023
|
De novo, hnRAC1-2I, 209-G{iodoF}GGNDNFG-217, derivative of hnRNPA1
| synthetic
| 209-217
| cryoEM
| 3.71
|  |
 |
8ikb
|
Li et al., 2023
|
De novo, hnRAC1-8I, 209-GFGGNDN{iodoF}G-217, derivative of hnRNPA1
| synthetic
| 209-217
| cryoEM
| 2.98
|  |
 |
8ikp
|
Li et al., 2023
|
De novo, hnRAC1-2I-8I, 209-G{iodoF}GGNDN{iodoF}G-217, derivative of hnRNPA1
| synthetic
| 209-217
| cryoEM
| 3.75
|  |
 |
8iks
|
Li et al., 2023
|
De novo, DIP-2I-8I, 209-G{iodoF}GNGNG{iodoF}G-217, polymorph 1, homolog of hnRNPA1
| Synthetic
| 209-217
| cryoEM
| 3.71
|  |
 |
8iy7
|
Li et al., 2023
|
De novo, DIP-2I-8I, 209-G{iodoF}GNGNG{iodoF}G-217, polymorph 2, homolog of hnRNPA1
| Synthetic
| 209-217
| cryoEM
| 3.75
|  |
 |
8izz
|
Li et al., 2023
|
FUS LC Domain
| recombinant
| 37-97
| ssNMR
| N/A
|  |
 |
5w3n
|
Murray et al., 2017
|
FUS LC Domain
| recombinant
| 112-150
| cryoEM
| 2.62
|  |
 |
6xfm
|
Lee et al., 2021
|
FUS LC Domain
| recombinant
| 34-124
| cryoEM
| 2.90
|  |
 |
7vqq
|
Sun et al., 2021
|
Glucagon
| Synthetic
| 1-29
| ssNMR
| N/A
|  |
 |
6nzn
|
Gelenter et al., 2019
|
Glucagon
| Synthetic
| 1-29
| cryoEM
| 3.90
|  |
 |
7xm8
|
Jeong et al., 2022 biorxiv
|
HET-s (218-289)
| recombinant
| 224-283
| ssNMR
| N/A
|  |
 |
2rnm
|
Wasmer et al., 2008
|
hnRNPA1
| Human, core segment 209-GFGGNDNFG-217, synthetic, reversible assembly
| 209-217
| cryoEM
| 3.69
|  |
 |
8ik7
|
Li et al., 2023
|
hnRNPA1
| Human, segment 186-320, recombinant
| 251-295
| cryoEM
| 2.8
|  |
 |
7bx7
|
Sun et al., 2020
|
hnRNPA1
| Human, full-length, recombinant
| 251-295
| cryoEM
| 3.32
|  |
 |
7zj2
|
Sharma et al., 2023
|
hnRNPA2
| recombinant
| 263-319
| cryoEM
| 3.1
|  |
 |
6wqk
|
Lu et al., 2020
|
hnRNPA2 D290V mutation
| Human, recombinant, fibril polymorph PM1
| 263-316
| cryoEM
| 3.30
|  |
 |
8du2
|
Lu et al., 2023
|
hnRNPA2 D290V mutation
| Human, recombinant, fibril polymorph PM2
| 263-316
| cryoEM
| 3.20
|  |
 |
8duw
|
Lu et al., 2023
|
hnRNPA2 D290V mutation
| Human, recombinant, fibril polymorph PM3
| 263-313
| cryoEM
| 3.90
|  |
 |
8ec7
|
Lu et al., 2023
|
hnRNPDL-2
| Human, recombinant
| 345-395
| cryoEM
| 2.50
|  |
 |
7zir
|
Garcia-Pardo et al., 2023
|
insulin
| Human, recombinant, pH 2, fibril type II
| A2-20, B5-19
| cryoEM
| 3.20
|  |
 |
8sbd
|
Wang et al., 2023
|
insulin
| Human, recombinant, pH 1.9
| A1-21, B1-21
| ssNMR
| N/A
|  |
 |
8rvt
|
Suladze et al., 2024
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, SUMO-tagged, recombinant
| 14-37
| cryoEM
| 3.70
|  |
 |
6vw2
|
Cao et al., 2020
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic, seeded with fibrils from a Type 2 Diabetes Patient, Polymorph 2
| 6-37
| cryoEM
| 3.9
|  |
 |
7m62
|
Cao et al., 2021
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic, seeded with fibrils from a Type 2 Diabetes Patient, Polymorph 3
| 13-37
| cryoEM
| 4.0
|  |
 |
7m64
|
Cao et al., 2021
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic
| 13-37
| cryoEM
| 4.2
|  |
 |
6y1a
|
Röder et al., 2020
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic
| 13-37
| cryoEM
| 3.6
|  |
 |
6zrf
|
Gallardo et al., 2020
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic
| 13-37
| cryoEM
| 4.01
|  |
 |
8r4i
|
Valli et al., 2024
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, amidated C-terminus, synthetic, 3 weeks incubation, lag phase, 2PF, P-fold
| 12-37
| cryoEM
| 3.00
|  |
 |
8awt
|
Wilkinson et al., 2023
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic, seeded with fibrils from a Type 2 Diabetes Patient, Polymorph 1
| 13-37
| cryoEM
| 3.8
|  |
 |
7m61
|
Cao et al., 2021
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, synthetic, amidated C-terminus, 6 weeks incubation, growth phase, 2PF, L-fold
| 10-37
| cryoEM
| 3.40
|  |
 |
8az0
|
Wilkinson et al., 2023
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, synthetic, amidated C-terminus, 22 weeks incubation, plateau phase, 2PF, L-fold
| 10-37
| cryoEM
| 2.20
|  |
 |
8az4
|
Wilkinson et al., 2023
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, synthetic, amidated C-terminus, 22 weeks incubation, plateauphase, 4PF, L-fold and U-fold
| 9-37
| cryoEM
| 3.10
|  |
 |
8az6
|
Wilkinson et al., 2023
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, synthetic, amidated C-terminus, 22 weeks incubation, plateauphase, 4PF, L-fold and J-fold
| 9-37
| cryoEM
| 2.90
|  |
 |
8az7
|
Wilkinson et al., 2023
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, synthetic, amidated C-terminus, 6 weeks incubation, growth phase, 2PF, C-fold
| 13-37
| cryoEM
| 3.10
|  |
 |
8az1
|
Wilkinson et al., 2023
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, synthetic, amidated C-terminus
| 15-37
| cryoEM
| 3.90
|  |
 |
6zrq
|
Gallardo et al., 2020
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, synthetic, amidated C-terminus
| 15-37
| cryoEM
| 4.00
|  |
 |
6zrr
|
Gallardo et al., 2020
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, synthetic, amidated C-terminus, 6 weeks incubation, growth phase, 3PF, C-fold and U-fold
| 11-37
| cryoEM
| 3.40
|  |
 |
8az2
|
Wilkinson et al., 2023
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, synthetic, amidated C-terminus, 6 weeks incubation, growth phase, 4PF, C-fold and U-fold
| 11-37
| cryoEM
| 3.40
|  |
 |
8az3
|
Wilkinson et al., 2023
|
Islet Amyloid Polypeptide (IAPP)
| Human, S20G mutation, synthetic, amidated C-terminus, 22 weeks incubation, plateauphase, 4PF, C-fold and U-fold
| 11-37
| cryoEM
| 2.30
|  |
 |
8az5
|
Wilkinson et al., 2023
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic, seeded with fibrils from a Type 2 Diabetes Patient, Polymorph 4
| 6-37
| cryoEM
| 4.10
|  |
 |
7m65
|
Cao et al., 2021
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic, no salt, slim form (SF)
| 11-37
| cryoEM
| 3.6
|  |
 |
7ykw
|
Li et al., 2022
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic, no salt, thick form type 1 (TF1)
| 1-37
| cryoEM
| 3.2
|  |
 |
7yl3
|
Li et al., 2022
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic, no salt, thick form type 2 (TF2)
| 1-37
| cryoEM
| 3.2
|  |
 |
7yl0
|
Li et al., 2022
|
Islet Amyloid Polypeptide (IAPP)
| Human, wild type, amidated C-terminus, synthetic, no salt, thick form type 3 (TF3)
| 1-37
| cryoEM
| 3.3
|  |
 |
7yl7
|
Li et al., 2022
|
LECT2
| Human, recombinant
| 55-74
| cryoEM
| 2.72
|  |
 |
8g2v
|
Richards et al., 2023
|
Light Chain λ1, Antibody
| Extracted from heart of a human with systemic AL amyloidosis
| 9-52, 68-108
| cryoEM
| 3.1
|  |
 |
7nsl
|
Radamaker et al., 2021
|
Light Chain λ1, Antibody
| Extracted from heart of a human with cardiac AL amyloidosis
| 15-105
| cryoEM
| 4.0
|  |
 |
6ic3
|
Radamaker et al., 2019
|
Light Chain λ3, Antibody
| Extracted from heart of a human with cardiac AL amyloidosis, patient FOR010
| 13-49, 61-106
| cryoEM
| 2.25
|  |
 |
8r47
|
Karimi-Farsijani et al., 2024
|
Light Chain λ3, Antibody
| Extracted from heart of a human with cardiac AL amyloidosis, conformation A
| 9-49, 60-107
| cryoEM
| 3.2
|  |
 |
6z1o
|
Radamaker et al., 2021
|
Light Chain λ3, Antibody
| Extracted from heart of a human with cardiac AL amyloidosis, patient FOR103
| 13-49, 61-106
| cryoEM
| 2.25
|  |
 |
9eme
|
Karimi-Farsijani et al., 2024
|
Light Chain λ3, Antibody
| Extracted from heart of a human with AL amyloidosis, AL59, unbent polymorph
| 1-118
| cryoEM
| 3.60
|  |
 |
9faa
|
Schulte et al., 2024
|
Light Chain λ3, Antibody
| Extracted from heart of a human with AL amyloidosis, AL59, mixed polymorph
| 1-117
| cryoEM
| 3.90
|  |
 |
9fac
|
Schulte et al., 2024
|
Light Chain λ3, Antibody
| Extracted from heart of a human with AL amyloidosis, AL59, bent polymorph
| 1-117
| cryoEM
| 3.90
|  |
 |
9fab
|
Schulte et al., 2024
|
Light Chain λ3, Antibody
| Extracted from heart of a human with cardiac AL amyloidosis, conformation B
| 9-49, 68-107
| cryoEM
| 3.4
|  |
 |
6z1i
|
Radamaker et al., 2021
|
Light Chain λ6, Antibody
| Extracted from heart of a human with amyloid cardiomyopathy
| 1-37, 66-105
| cryoEM
| 3.3
|  |
 |
6hud
|
Swuec et al., 2019
|
Light Chain λ6, Antibody
| Extracted from kidney of a human with AL amyloidosis
| 1-37, 66-105
| cryoEM
| 4.0
|  |
 |
8cpe
|
Puri et al., 2023
|
Nup98
| Human, recombinant, polymorph 1
| 85-124
| cryoEM
| 2.76
|  |
 |
7q64
|
Ibáñez de Opakua et al., 2022
|
Nup98
| Human, recombinant, polymorph 2
| 85-124
| cryoEM
| 3.32
|  |
 |
7q65
|
Ibáñez de Opakua et al., 2022
|
Nup98
| Human, recombinant, polymorph 3
| 85-121
| cryoEM
| 2.79
|  |
 |
7q66
|
Ibáñez de Opakua et al., 2022
|
Nup98
| Human, recombinant, polymorph 4
| 87-119
| cryoEM
| 3.37
|  |
 |
7q67
|
Ibáñez de Opakua et al., 2022
|
Nup98
| Human, segment 298-327, synthetic
| 299-324
| cryoEM
| 2.67
|  |
 |
8ci8
|
Ibáñez de Opakua et al., 2024
|
Orb2
|
Drosophila, brain extracted
|
176-206
|
cryoEM
|
2.6
|
 |
 |
6vps
|
Hervás et al., 2020
|
PSMα1
| Staphylococcus aureus, synthetic
| 1-21
| cryoEM
| 3.50
|  |
 |
9atw
|
Hansen et al., 2024
|
Prion Protein
| Human, recombinant
| 106-145
| cryoEM
| 3.5
|  |
 |
6uur
|
Glynn et al., 2020
|
Prion Protein
| Human, recombinant
| 94-144
| cryoEM
| 2.88
|  |
 |
8wzx
|
Lee et al., 2024
|
Prion Protein
| Human, V129+F198S mutations, extracted from patient with Gerstmann-Sträussler-Scheinker disease, type I filament
| 80-141
| cryoEM
| 3.29
|  |
 |
7umq
|
Hallinan et al., 2022
|
Prion Protein
| Human, V129+F198S mutations, extracted from patient with Gerstmann-Sträussler-Scheinker disease, type IIb filament
| 80-141
| cryoEM
| 3.13
|  |
 |
7un5
|
Hallinan et al., 2022
|
Prion Protein
| Human, recombinant
| 170-229
| cryoEM
| 2.7
|  |
 |
6lni
|
Wang et al., 2020
|
Prion Protein
| Human, E196K mutation, recombinant
| 175-217
| cryoEM
| 3.07
|  |
 |
7dwv
|
Wang et al., 2021
|
Prion Protein
| Mouse, PrP23-144, recombinant, polymorph 1
| 108-141
| cryoEM
| 3.92
|  |
 |
8dja
|
Li et al., 2022
|
Prion Protein
| Human, Y145Stop mutation, recombinant
| 108-141
| cryoEM
| 2.86
|  |
 |
7rl4
|
Li et al., 2022
|
Prion Protein
| Syrian hamster, recombinant, prepared in acidic solution
| 119-143
| cryoEM
| 2.20
|  |
 |
7yat
|
Chen et al., 2022
|
Prion Protein
| Syrian hamster, infectious, 263K strain, extracted from clinically ill hamster brain
| 95-227
| cryoEM
| 3.14
|  |
 |
7lna
|
Kraus et al., 2021
|
Prion Protein
| Mouse, anchorless, aRML prion strain, infectious, extracted from brains of terminally ill mice
| 93-230
| cryoEM
| 3.00
|  |
 |
7td6
|
Hoyt et al., 2022
|
Prion Protein
| Mouse, anchorless, aRML prion strain, infectious, extracted from brains of terminally ill mice
| 94-225
| cryoEM
| 2.70
|  |
 |
7qig
|
Manka et al., 2022
|
Prion Protein
| Mouse, a22L prion strain, infectious, extracted from brains of terminally ill mice
| 94-226
| cryoEM
| 3.20
|  |
 |
8efu
|
Hoyt et al., 2022
|
Prion Protein
| Mouse, ME7 prion strain, infectious, extracted from brains of terminally ill mice
| 94-229
| cryoEM
| 2.60
|  |
 |
8a00
|
Manka et al., 2023
|
RIPK1(496-583) + RIPK3(388-518), human
| recombinant
| 448-462, 532-549
| ssNMR
| N/A
|  |
 |
5v7z
|
Mompeán et al., 2018
|
RIPK3(388-518) human
| recombinant
| 448-469
| cryoEM
| 4.24
|  |
 |
7da4
|
Wu et al., 2021
|
RIPK1(516-539)
| mouse, recombinant
| 516-539
| ssNMR
| N/A
|  |
 |
8ib0
|
Liu et al., 2023 unpublished
|
RIPK3(418-518) human
| recombinant
| 447-475
| ssNMR
| N/A
|  |
 |
7dac
|
Wu et al., 2021
|
Serum Amyloid A, mouse
| Extracted from spleen of a mouse with systemic AA amyloidosis, morphology I
| 1-69
| cryoEM
| 3.0
|  |
 |
6dso
|
Liberta et al., 2019
|
Serum Amyloid A, mouse
| recombinant, seeded by ex vivo fibrils from mouse liver, morphology I
| 1-69
| cryoEM
| 2.69
|  |
 |
7ovt
|
Heerde et al., 2022
|
Serum Amyloid A, mouse
| Extracted from spleen of a mouse with systemic AA amyloidosis, morphology II
| 1-69
| cryoEM
| 3.5
|  |
 |
6zch
|
Bansal et al., 2021
|
Serum Amyloid A, mouse
|
recombinant, unseeded, in vitro morphology i
|
1-37
|
cryoEM
|
2.73
|
 |
 |
6zcf
|
Bansal et al., 2021
|
Serum Amyloid A, mouse
|
recombinant, unseeded, in vitro morphology ii
|
1-37
|
cryoEM
|
2.95
|
 |
 |
6zcg
|
Bansal et al., 2021
|
Serum Amyloid A, human
| Extracted from kidney of a human with AA amyloidosis, glomerular variant
| 2-55
| cryoEM
| 2.7
|  |
 |
6mst
|
Liberta et al., 2019
|
Serum Amyloid A, human
| Extracted from kidney of a human with AA amyloidosis, vascular variant
| 2-69
| cryoEM
| 2.56
|  |
 |
7zky
|
Banerjee et al., 2022
|
Serum Amyloid A, feline
| Extracted from kidney of a domestic short hair cat with AA amyloidosis
| 19-94
| cryoEM
| 3.30
|  |
 |
7zh7
|
Schulte et al., 2022
|
SH3 Domain of PI3-kinase
| recombinant
| 1-77
| cryoEM
| 3.4
|  |
 |
6r4r
|
Röder et al., 2019
|
Superoxide Dismutase
| recombinant, full-length
| 3-55, 86-153
| cryoEM
| 2.95
|  |
 |
7vzf
|
Wang et al., 2022
|
TAF15
| Human, extracted from FTLD-FET patient brain
| 7-99
| cryoEM
| 1.97
|  |
 |
8ons
|
Tetter et al., 2023
|
Tau
| Human, (297-391), recombinant, First Intermediate Amyloid (FIA) on Pathway to AD and CTE folds
| 302-316
| cryoEM
| 2.0
|  |
 |
8ppo
|
Lövestam et al., 2024
|
Tau
| Human, 3R+4R, extracted from Alzheimers Disease Patient brain, Paired Helical Filament (PHF)
| 306-378
| cryoEM
| 3.4
|  |
 |
5o3l
|
Fitzpatrick et al., 2017
|
Tau
| Human, 3R+4R, extracted Alzheimers Disease Patient brain, supernatant fraction, PHF
| 306-379
| cryoEM
| 3.10
|  |
 |
8azu
|
Stern et al., 2023
|
Tau
| Human, 3R+4R, extracted Alzheimers Disease Patient brain, extracellular vesicle fraction, PHF
| 305-379
| cryoEM
| 3.16
|  |
 |
8bgs
|
Fowler et al., 2024
|
Tau
| Human, 3R+4R, extracted Alzheimers Disease Patient brain, cellular fraction, PHF
| 305-379
| cryoEM
| 3.27
|  |
 |
8bgv
|
Fowler et al., 2024
|
Tau
| Human, extracted from an individual with Down Syndrome and Alzheimers Disease, Paired Helical Filament
| 306-378
| cryoEM
| 2.90
|  |
 |
8seh
|
Fernandez et al., 2024
|
Tau
| Human, 3R+4R, extracted from PrP Cerebral Amyloid Angiopathy Patient Brain, PHF
| 306-378
| cryoEM
| 3.00
|  |
 |
7mkf
|
Hallinan et al., 2021
|
Tau
| Human, 3R+4R, extracted from Gerstmann-Sträussler-Scheinker Patient Brain, PHF
| 305-379
| cryoEM
| 3.30
|  |
 |
7mkh
|
Hallinan et al., 2021
|
Tau
| Human, 3R+4R, extracted from Primary Age-Related Tauopathy Patient Brain Case 3, PHF
| 304-380
| cryoEM
| 2.76
|  |
 |
7nrq
|
Shi et al., 2021
|
Tau
| Human, extracted from an individual with Amyltrophic Lateral Sclerosis/Parkinsonism-dementia complex (ALS/PDC), Kii case 5, PHF AD fold
| 304-380
| cryoEM
| 3.30
|  |
 |
8otj
|
Qi et al., 2023
|
Tau
| Human, V337M mutant, extracted from individual with forontotemporal dementia, PHF
| 304-380
| cryoEM
| 2.80
|  |
 |
9eo7
|
Qi et al., 2024
|
Tau
| Human, R406W mutant, extracted from individual with forontotemporal dementia, PHF
| 304-380
| cryoEM
| 3.00
|  |
 |
9eog
|
Qi et al., 2024
|
Tau
| Human, extracted from individual with Down Syndrome, case 1, PHF-like
| 304-380
| cryoEM
| 2.70
|  |
 |
9bxi
|
Ghosh et al., 2024
|
Tau
| Human, extracted from individual with Down Syndrome, case 2, PHF-like
| 304-380
| cryoEM
| 3.10
|  |
 |
9bxq
|
Ghosh et al., 2024
|
Tau
| Human, isoform F, recombinant, heparin, polymorph PHF
| 304-379
| cryoEM
| 3.50
|  |
 |
8zx6
|
Tao et al., 2024 unpublished
|
Tau
| Human, extracted from Alzheimers Disease brain, PET ligand MK-6240
| 305-379
| cryoEM
| 2.31
|  |
 |
8uq7
|
Kunach et al., 2024
|
Tau
| Human, 3R+4R, extracted Alzheimers Disease Patient brain and Stained with PET ligand GTP-1
| 306-378
| cryoEM
| 2.70
|  |
 |
8fug
|
Merz et al., 2023
|
Tau
| Human, 3R+4R, extracted Alzheimers Disease Patient brain, PHF, PET ligand APN1607
| 304-380
| cryoEM
| 3.00
|  |
 |
7nrv
|
Shi et al., 2021
|
Tau
| Human, 3R+4R, extracted from Alzheimers Disease Patient brain, PHF, soaked with EGCG for 0 hours
| 304-379
| cryoEM
| 3.40
|  |
 |
7upe
|
Seidler et al., 2022
|
Tau
| Human, 3R+4R, extracted from Alzheimers Disease Patient brain, PHF, soaked in EGCG for 1 hour
| 306-379
| cryoEM
| 3.30
|  |
 |
7upf
|
Seidler et al., 2022
|
Tau
| Human, 3R+4R, extracted from Alzheimers Disease Patient brain, PHF, Soaked in EGCG for 3 hours
| 306-379
| cryoEM
| 3.80
|  |
 |
7upg
|
Seidler et al., 2022
|
Tau
| Human, segment 297-391, recombinant, PHF-like polymorph, 200 mM MgCl2, 200 rpm, filament type 4a
| 304-379
| cryoEM
| 3.20
|  |
 |
7ql4
|
Lövestam et al., 2022
|
Tau
| Human, segment 266-391 and 3R(297-391), recombinant, PHF-like polymorph
| 304-379
| cryoEM
| 3.46
|  |
 |
7ymn
|
Li et al., 2022
|
Tau
| Human, segment 297-391, recombinant, PHF, long crossover, with AD fold
| 304-379
| cryoEM
| 2.95
|  |
 |
8q8m
|
Lövestam et al., 2024
|
Tau
| Human, segment 297-391, recombinant, PHF with AD fold
| 304-379
| cryoEM
| 2.10
|  |
 |
8q8r
|
Lövestam et al., 2024
|
Tau
| Human, segment 297-407, S396E+S400E+T403E+S404E phosphomimetic mutations, recombinant, PHF with AD fold
| 306-379
| cryoEM
| 3.20
|  |
 |
9bbm
|
Duan et al., 2024
|
Tau
| Human, V337M mutant, isoform F (residues 1-441), recombinant, Paired Helical Filament (PHF)
| 306-379
| cryoEM
| 2.80
|  |
 |
9eoh
|
Qi et al., 2024
|
Tau
| Human, segment 297-391, recombinant, Triple Helical Filament, THF with AD fold
| 304-379
| cryoEM
| 2.68
|  |
 |
8q8s
|
Lövestam et al., 2024
|
Tau
| Human, segment 297-407, S396E+S400E+T403E+S404E phosphomimetic mutations, recombinant, Triple Helical Filament, THF with AD fold
| 307-378
| cryoEM
| 2.50
|  |
 |
9bbl
|
Duan et al., 2024
|
Tau
| Human, (297-391), recombinant, AD-like fold, LiCl, filament type 2c
| 304-378
| cryoEM
| 3.29
|  |
 |
7qjv
|
Lövestam et al., 2022
|
Tau
| V337M mutant, human, extracted from individual with forontotemporal dementia, Triple Filament (TF)
| 304-380
| cryoEM
| 2.30
|  |
 |
9eoe
|
Qi et al., 2024
|
Tau
| Human, 3R+4R, extracted from brain of a human with Alzheimer's Disease, Straight Filament (SF)
| 306-378
| cryoEM
| 3.4
|  |
 |
5o3t
|
Fitzpatrick et al., 2017
|
Tau
| Human, 3R+4R, extracted from Alzheimers Patient Brain, SF, PET ligand APN1607
| 304-380
| cryoEM
| 3.55
|  |
 |
7nrx
|
Shi et al., 2021
|
Tau
| Human, 3R+4R, extracted from PrP Cerebral Amyloid Angiopathy Patient Brain, SF
| 306-378
| cryoEM
| 3.07
|  |
 |
7mkg
|
Hallinan et al., 2021
|
Tau
| Human, 3R+4R, extracted from Primary Age-Related Tauopathy Patient Brain Case 3, SF, conformation 1
| 304-380
| cryoEM
| 2.68
|  |
 |
7nrs
|
Shi et al., 2021
|
Tau
| Human, 3R+4R, extracted from Primary Age-Related Tauopathy Patient Brain Case 3, SF, conformation 2
| 304-380
| cryoEM
| 2.68
|  |
 |
7nrt
|
Shi et al., 2021
|
Tau
| Human, extracted from an individual with Down Syndrome and Alzheimers Disease, SF
| 306-378
| cryoEM
| 2.90
|  |
 |
8sei
|
Fernandez et al., 2024
|
Tau
| Human, extracted from individual with Down Syndrome, case 1, SF-like
| 304-380
| cryoEM
| 3.00
|  |
 |
9bxo
|
Ghosh et al., 2024
|
Tau
| Human, extracted from individual with Down Syndrome, case 2, SF-like
| 304-380
| cryoEM
| 3.20
|  |
 |
9bxr
|
Ghosh et al., 2024
|
Tau
| V337M mutant, human, extracted from individual with forontotemporal dementia, Straight Filament (SF)
| 304-380
| cryoEM
| 3.30
|  |
 |
9eo9
|
Qi et al., 2024
|
Tau
| Human, (297-408), S396D+S400D+T403D mutations, recombinant, filament type 42a
| 304-379
| cryoEM
| 3.13
|  |
 |
7qki
|
Lövestam et al., 2022
|
Tau
| Human, (297-391), recombinant, Late Intermediate Amyloid on Pathway to AD fold, AD-LIA2
| 304-379
| cryoEM
| 2.95
|  |
 |
8q88
|
Lövestam et al., 2024
|
Tau
| Human, isoform F, recombinant, heparin, polymorph 3
| 304-379
| cryoEM
| 3.40
|  |
 |
8zwl
|
Tao et al., 2024 unpublished
|
Tau (258-391)
| recombinant, phosphoglycerate, 700rpm, filament type 39a
| 304-379
| cryoEM
| 2.80
|  |
 |
7qkk
|
Lövestam et al., 2022
|
Tau 3R
| Extracted from human SH-SY5Y cell culture, seeded with brain of a patient with Alzheimers Disease
| 273-274,306-380
| cryoEM
| 2.5
|  |
 |
8ore
|
Tarutani et al., 2023
|
Tau (266-391)(297-391)
| recombinant, MgCl2 and NaCl, filament type 14a
| 304-379
| cryoEM
| 2.57
|  |
 |
7qku
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to AD fold, AD-LIA6
| 304-379
| cryoEM
| 3.04
|  |
 |
8q8d
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to AD fold, AD-LIA7
| 304-379
| cryoEM
| 3.04
|  |
 |
8q8l
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to AD fold, AD-LIA5
| 304-379
| cryoEM
| 2.93
|  |
 |
8q8f
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA11
| 303-379
| cryoEM
| 3.04
|  |
 |
8q9a
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to AD fold, AD-MIA2
| 303-380
| cryoEM
| 2.23
|  |
 |
8q2j
|
Lövestam et al., 2024
|
Tau
| Human, 4R, Extracted from brain of a patient with Chronic Traumatic Encephalopathy, filament type I (CTE-I)
| 305-379
| cryoEM
| 2.30
|  |
 |
6nwp
|
Falcon et al., 2019
|
Tau
| Human, extracted from brain of an individual with Vacuolar Tauopathy and VCP mutation D395G, (CTE-I fold)
| 305-379
| cryoEM
| 2.30
|  |
 |
9erm
|
Qi et al., 2024
|
Tau
| Human, 4R, extracted from brain of an individual with Subacute Sclerosing Panencephalitis, (CTE-I fold)
| 305-379
| cryoEM
| 2.30
|  |
 |
8caq
|
Qi et al., 2023
|
Tau
| Human, extracted from an individual with Amyltrophic Lateral Sclerosis/Parkinsonism-dementia complex (ALS/PDC), Guam case 3, CTE-I fold
| 305-379
| cryoEM
| 2.00
|  |
 |
8ot6
|
Qi et al., 2023
|
Tau
| Human, 4R, Extracted from brain of a patient with Chronic Traumatic Encephalopathy, filament type I (CTE-I), complex with PET ligand flortaucipir
| 305-379
| cryoEM
| 2.6
|  |
 |
8byn
|
Shi et al., 2022
|
Tau(297-391)
| Human, recombinant, (CTE-I fold)
| 305-379
| cryoEM
| 2.65
|  |
 |
8q9m
|
Lövestam et al., 2024
|
Tau
| Human, extracted from an individual with Amyltrophic Lateral Sclerosis/Parkinsonism-dementia complex (ALS/PDC), Kii case 5, CTE-I fold
| 305-379
| cryoEM
| 2.10
|  |
 |
8otg
|
Qi et al., 2023
|
Tau
| Human, 4R, extracted from brain of a patient with Chronic Traumatic Encephalopathy, filament type II (CTE-II)
| 305-379
| cryoEM
| 3.40
|  |
 |
6nwq
|
Falcon et al., 2019
|
Tau 4R
| Human, extracted from brain of an individual with Subacute Sclerosing Panencephalitis, (CTE-II fold)
| 305-379
| cryoEM
| 3.70
|  |
 |
8cax
|
Qi et al., 2023
|
Tau
| Human, extracted from an individual with Amyltrophic Lateral Sclerosis/Parkinsonism-dementia complex (ALS/PDC), Guam case 1, CTE-II fold
| 305-379
| cryoEM
| 3.20
|  |
 |
8otc
|
Qi et al., 2023
|
Tau
| Human, extracted from brain of an individual with Vacuolar Tauopathy and VCP mutation D395G, (CTE-II fold)
| 305-379
| cryoEM
| 2.50
|  |
 |
9ern
|
Qi et al., 2024
|
Tau (297-391)
| Human, recombinant, filament type 8a, CTE-II-like
| 305-379
| cryoEM
| 2.81
|  |
 |
7qjw
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, CTE-II fold
| 305-379
| cryoEM
| 3.35
|  |
 |
8qjj
|
Lövestam et al., 2024
|
Tau
| Human, extracted from an individual with Amyltrophic Lateral Sclerosis/Parkinsonism-dementia complex (ALS/PDC), Kii case 5, CTE-II fold
| 305-379
| cryoEM
| 3.40
|  |
 |
8oth
|
Qi et al., 2023
|
Tau(297-391)
| Human, recombinant, CTE fold type II (CTE-II-like)
| 305-379
| cryoEM
| 3.10
|  |
 |
8q9o
|
Lövestam et al., 2024
|
Tau
| Human, extracted from brain of an individual with Vacuolar Tauopathy and VCP mutation D395G, (CTE-III fold)
| 305-379
| cryoEM
| 2.90
|  |
 |
9ero
|
Qi et al., 2024
|
Tau
| Human, extracted from an individual with Amyltrophic Lateral Sclerosis/Parkinsonism-dementia complex (ALS/PDC), Guam case 3, CTE-III fold
| 305-379
| cryoEM
| 3.40
|  |
 |
8ot9
|
Qi et al., 2023
|
Tau
| Human, extracted from an individual with Chronic Traumatic Encephalopathy, case 2, CTE-III fold
| 305-379
| cryoEM
| 2.70
|  |
 |
8oti
|
Qi et al., 2023
|
Tau (266-391)(297-391)
| recombinant, CTE-like fold, MgSO4, NaCl, filament type 15b
| 306-378
| cryoEM
| 3.16
|  |
 |
7qkx
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to CTE fold, CTE-LIA4
| 306-378
| cryoEM
| 2.18
|  |
 |
8q9h
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to CTE fold, CTE-LIA13
| 306-379
| cryoEM
| 3.20
|  |
 |
8q9k
|
Lövestam et al., 2024
|
Tau (266-391)(297-391)
| recombinant, CTE-like fold, MgSO4, NaCl, filament type 15c
| 306-377
| cryoEM
| 3.13
|  |
 |
7ql0
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to CTE fold, CTE-LIA3
| 305-379
| cryoEM
| 1.91
|  |
 |
8q9f
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to CTE fold, CTE-LIA5
| 306-378
| cryoEM
| 2.65
|  |
 |
8q9g
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to CTE fold, CTE-LIA7
| 306-378
| cryoEM
| 2.96
|  |
 |
8q9j
|
Lövestam et al., 2024
|
Tau (266-391)(297-391)
| recombinant, CTE-like fold, MgSO4, NaCl, filament type 15a
| 309-377
| cryoEM
| 3.23
|  |
 |
7qkv
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to CTE fold, CTE-LIA14
| 306-378
| cryoEM
| 2.76
|  |
 |
8q9l
|
Lövestam et al., 2024
|
Tau (266-391)
| recombinant, CTE-like fold, phosphate-buffered saline, filament type 23a
| 306-378
| cryoEM
| 3.34
|  |
 |
7ql1
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to CTE fold, CTE-LIA6
| 306-378
| cryoEM
| 2.56
|  |
 |
8q9i
|
Lövestam et al., 2024
|
Tau (266-391)(297-391)
| recombinant, LiCl, filament type 9b
| 305-378
| cryoEM
| 3.40
|  |
 |
7qjz
|
Lövestam et al., 2022
|
Tau (266-391)(297-391)
| recombinant, KCl, filament type 10b
| 305-388
| cryoEM
| 2.59
|  |
 |
7r5h
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to AD fold, AD-MIA1
| 303-379
| cryoEM
| 2.02
|  |
 |
8q27
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to AD fold, AD-MIA10
| 304-378
| cryoEM
| 1.92
|  |
 |
8q8c
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to AD fold, AD-MIA6
| 306-379
| cryoEM
| 2.82
|  |
 |
8q7l
|
Lövestam et al., 2024
|
Tau
| Human, isoform F, recombinant, heparin, polymorph 4
| 303-378
| cryoEM
| 3.20
|  |
 |
8zwm
|
Tao et al., 2024 unpublished
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to AD fold, AD-MIA7
| 304-379
| cryoEM
| 3.26
|  |
 |
8q7m
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to AD fold, AD-LIA4
| 304-379
| cryoEM
| 3.81
|  |
 |
8q8e
|
Lövestam et al., 2024
|
Tau (266-391)(297-391)
| recombinant, KCl, filament type 10a
| 306-379
| cryoEM
| 1.92
|  |
 |
7qk5
|
Lövestam et al., 2022
|
Tau (297-394)
| recombinant, phosphate buffered saline, filament type 35d
| 305-379
| cryoEM
| 3.03
|  |
 |
7qk1
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Late Intermediate Amyloid on Pathway to AD fold, AD-LIA8
| 304-379
| cryoEM
| 3.21
|  |
 |
8qcp
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA12
| 305-379
| cryoEM
| 2.75
|  |
 |
8qcr
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA14
| 305-379
| cryoEM
| 3.40
|  |
 |
8q9c
|
Lövestam et al., 2024
|
Tau (300-391)
| recombinant, phosphate buffered saline, filament type 36a
| 308-378
| cryoEM
| 2.61
|  |
 |
7qk2
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA4
| 304-378
| cryoEM
| 2.85
|  |
 |
8q8w
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA7
| 305-379
| cryoEM
| 3.16
|  |
 |
8q8z
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA5
| 303-379
| cryoEM
| 2.54
|  |
 |
8q8x
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA6
| 306-379
| cryoEM
| 2.88
|  |
 |
8q8y
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to AD fold, AD-MIA11
| 304-378
| cryoEM
| 3.00
|  |
 |
8q7t
|
Lövestam et al., 2024
|
Tau (266-391)(297-391)
| recombinant, MgCl2, NaCl, filament type 14b
| 305-379
| cryoEM
| 3.26
|  |
 |
7qkj
|
Lövestam et al., 2022
|
Tau (266-391)(297-391)
| recombinant, NaCl, filament type 8b
| 308-378
| cryoEM
| 3.32
|  |
 |
7ql3
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to AD fold, AD-MIA5
| 304-378
| cryoEM
| 3.72
|  |
 |
8q7f
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA18
| 308-379
| cryoEM
| 2.97
|  |
 |
8q9e
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA10
| 308-378
| cryoEM
| 2.70
|  |
 |
8q99
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA1
| 308-378
| cryoEM
| 3.30
|  |
 |
8q8u
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to AD fold, AD-MIA8
| 304-378
| cryoEM
| 3.28
|  |
 |
8q7p
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA3
| 305-379
| cryoEM
| 3.80
|  |
 |
8q8v
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA13
| 305-379
| cryoEM
| 3.10
|  |
 |
8q9b
|
Lövestam et al., 2024
|
Tau (266-391)+(297-391)
| recombinant, NaHCO3, NaCl, filament type 16a
| 304-379
| cryoEM
| 2.75
|  |
 |
7r4t
|
Lövestam et al., 2022
|
Tau (266-391)(297-391)
| recombinant, LiCl, filament type 9a
| 305-379
| cryoEM
| 3.14
|  |
 |
7qjy
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA6
| 308-378
| cryoEM
| 2.99
|  |
 |
8q97
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA8
| 305-379
| cryoEM
| 1.75
|  |
 |
8q98
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to AD fold, AD-MIA3
| 305-379
| cryoEM
| 2.88
|  |
 |
8q2k
|
Lövestam et al., 2024
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to CTE fold, CTE-MIA15
| 305-379
| cryoEM
| 3.16
|  |
 |
8q9d
|
Lövestam et al., 2024
|
Tau (266-391)(297-391)
| recombinant, ZnCl2, filament type 11a
| 304-379
| cryoEM
| 2.07
|  |
 |
7qkl
|
Lövestam et al., 2022
|
Tau(297-391)
| Human, recombinant, Middle Intermediate Amyloid on Pathway to AD fold, AD-MIA4
| 307-378
| cryoEM
| 2.20
|  |
 |
8q2l
|
Lövestam et al., 2024
|
Tau (297-391)
| recombinant, 700 rpm, filament type 34b
| 304-378
| cryoEM
| 2.99
|  |
 |
7qjx
|
Lövestam et al., 2022
|
Tau 3R
| Extracted from brain of a human with Pick's Disease
| 254-274, 306-378
| cryoEM
| 3.2
|  |
 |
6gx5
|
Falcon et al., 2018
|
Tau 3R ΔK281 mutation
| Extracted from brain of a human with Pick's Disease and MAPT ΔK281 mutation
| 254-274, 306-378
| cryoEM
| 2.61
|  |
 |
8p34
|
Schweighauser et al., 2023
|
Tau (297-391)
| recombinant, spindle-like fold
| 304-362
| cryoEM
| 2.54
|  |
 |
7ypg
|
Li et al., 2022
|
Tau 4R
| Extracted from brain of a human with Corticobasal Degeneration (CBD), Filament Type I
| 274-380
| cryoEM
| 3.2
|  |
 |
6tjo
|
Zhang et al., 2020
|
Tau 4R
| Extracted from Argyrophilic Grain Disease (AGD) Patient Brain, Filament Type 1
| 273-387
| cryoEM
| 3.30
|  |
 |
7p6d
|
Shi et al., 2021
|
Tau 4R
| Extracted from human SH-SY5Y cell culture, seeded with brain of a patient with Corticobasal Degeneration (CBD), Filament Type I
| 277-377
| cryoEM
| 2.5
|  |
 |
8orf
|
Tarutani et al., 2023
|
Tau 4R
| Extracted from human SH-SY5Y cell culture, seeded with brain of a patient with Corticobasal Degeneration (CBD), Filament Type II
| 277-362
| cryoEM
| 2.3
|  |
 |
8org
|
Tarutani et al., 2023
|
Tau 4R
| Extracted from brain of a human with Corticobasal Degeneration (CBD), Filament Type II
| 274-380
| cryoEM
| 3.0
|  |
 |
6tjx
|
Zhang et al., 2020
|
Tau 4R
| Extracted from Argyrophilic Grain Disease (AGD) Patient Brain, Filament Type 2
| 274-381
| cryoEM
| 3.40
|  |
 |
7p6e
|
Shi et al., 2021
|
Tau (198-399)
| Human, recombinant, observed at 24° C
| 274-325
| ssNMR
| N/A
|  |
 |
8g54
|
El Mammeri et al., 2023
|
Tau (198-399)
| Human, recombinant, observed at 12° C
| 264-326
| ssNMR
| N/A
|  |
 |
8g55
|
El Mammeri et al., 2023
|
Tau 4R
| Extracted from Progressive Supranuclear Palsy (PSP) Patient Brain
| 272-381
| cryoEM
| 2.70
|  |
 |
7p65
|
Shi et al., 2021
|
Tau 4R
| Extracted from Progressive Supranuclear Palsy (PSP) Patient Brain, Case 1
| 272-381
| cryoEM
| 4.20
|  |
 |
7u0z
|
Chang et al., 2022
|
Tau 4R
| Extracted from Globular Glial Tauopathy (GGT) Patient Brain, Filament Type 1
| 272-379
| cryoEM
| 3.00
|  |
 |
7p66
|
Shi et al., 2021
|
Tau 4R
| Extracted from Globular Glial Tauopathy (GGT) Patient Brain, filament type 2
| 272-379
| cryoEM
| 3.10
|  |
 |
7p67
|
Shi et al., 2021
|
Tau 4R
| Extracted from Globular Glial Tauopathy (GGT) Patient Brain, Filament Type 3
| 272-379
| cryoEM
| 2.90
|  |
 |
7p68
|
Shi et al., 2021
|
Tau
| Human, isoform 0N4R, S396E+T403E+S404E phosphomimetic mutations, sites recognized by PH1 antibody, recombinant
| 273-362
| cryoEM
| 2.40
|  |
 |
8ttn
|
Mammeri et al., 2024
|
Tau 4R
| Extracted from Limbic-Predominant Neuronal Inclusion Body 4R Tauopathy (LNT) Patient Brain, Filament Type 1a
| 272-379
| cryoEM
| 1.90
|  |
 |
7p6a
|
Shi et al., 2021
|
Tau 4R
| Extracted from Limbic-Predominant Neuronal Inclusion Body 4R Tauopathy (LNT) Patient Brain, Filament Type 1b
| 272-379
| cryoEM
| 2.50
|  |
 |
7p6b
|
Shi et al., 2021
|
Tau 4R
| Extracted from Limbic-Predominant Neuronal Inclusion Body 4R Tauopathy (LNT) Patient Brain, Filament Type 2
| 272-379
| cryoEM
| 2.20
|  |
 |
7p6c
|
Shi et al., 2021
|
Tau
| Human, P301L mutation, extracted from transgenic mouse line rTg4510 brain
| 249-261, 274-346
| cryoEM
| 3.28
|  |
 |
8wcp
|
Schweighauser et al., 2023
|
Tau 4R P301S mutation
| Human, extracted from transgenic mouse line TG2541 brain
| 249-345
| cryoEM
| 3.09
|  |
 |
8q96
|
Schweighauser et al., 2023
|
Tau 4R P301S mutation
| Human, extracted from transgenic mouse line PS19 brain
| 271-364
| cryoEM
| 3.05
|  |
 |
8q92
|
Schweighauser et al., 2023
|
Tau
| Human, isoform 0N4R, S202E+T205E+S208E phosphomimetic mutations, sites recognized by AT8 antibody, recombinant
| 304-330, 351-440
| cryoEM
| 2.60
|  |
 |
8ttl
|
Mammeri et al., 2024
|
Tau40 and RNA
| recombinant and grown with RNA
| 391-426
| cryoEM
| 3.40
|  |
 |
7sp1
|
Abskharon et al., 2022
|
Tau 0N4R with phosphoserine
| recombinant, filament type 47a
| 376-441
| cryoEM
| 1.86
|  |
 |
7qky
|
Lövestam et al., 2022
|
Tau (266-391)(297-391)
| recombinant, CuCl2, filament type 12a
| 309-360, 305-335
| cryoEM
| 2.83
|  |
 |
7qkf
|
Lövestam et al., 2022
|
Tau 4R
| recombinant, Heparin Induced, Snake Polymorph
| 272-330
| cryoEM
| 3.3
|  |
 |
6qjh
|
Zhang et al., 2019
|
Tau 4R
| recombinant, Heparin Induced, Twister Polymorph
| 274-292, 304-321
| cryoEM
| 3.3
|  |
 |
6qjm
|
Zhang et al., 2019
|
Tau 4R
| recombinant, Heparin Induced, Jagged Polymorph
| 274-290, 304-321
| cryoEM
| 3.5
|  |
 |
6qjp
|
Zhang et al., 2019
|
Tau (258-391)
| recombinant, heparan sulfate, 700 rpm, filament type 40a
| 275-328
| cryoEM
| 2.27
|  |
 |
7qk6
|
Lövestam et al., 2022
|
Tau (258-391)
| recombinant, phosphoglycerate, 700 rpm, filament type 39a
| 275-328
| cryoEM
| 3.36
|  |
 |
7qkg
|
Lövestam et al., 2022
|
Tau (266-391) S356D
| recombinant, KCl, filament type 44a
| 275-328
| cryoEM
| 2.32
|  |
 |
7qkw
|
Lövestam et al., 2022
|
Tau (244-391)
| recombinant, Na4P2O7, filament type 20a
| 275-324
| cryoEM
| 2.95
|  |
 |
7ql2
|
Lövestam et al., 2022
|
Tau (258-391)
| recombinant, 700 rpm, filament type 38a
| 270-330
| cryoEM
| 2.44
|  |
 |
7qk3
|
Lövestam et al., 2022
|
Tau (266-391) S356D
| recombinant, NaCl, filament type 45a
| 274-328
| cryoEM
| 2.66
|  |
 |
7qkm
|
Lövestam et al., 2022
|
Tau 3R
| recombinant, Heparin Induced
| 272-274,306-330
| cryoEM
| 3.5
|  |
 |
6qjq
|
Zhang et al., 2019
|
Tau (258-391)
| recombinant, sodium azide, filament type 41a
| 277-317
| cryoEM
| 3.17
|  |
 |
7qkh
|
Lövestam et al., 2022
|
Tau (305-379)
| recombinant, filament type 27a
| 307-317
| cryoEM
| 2.65
|  |
 |
7qkz
|
Lövestam et al., 2022
|
Tau (263-280), acetylated K274 and K280
| human, synthetic
| 263-280
| cryoEM
| 3.88
|  |
 |
8fnz
|
Li et al., 2023
|
Tau
| Human, PAM4 segment 350-362, amidated C-terminus, acetylated N-terminus, synthetic, fibril type 1
| 350-362
| cryoEM
| 2.60
|  |
 |
8oh2
|
Louros et al., 2024
|
Tau
| Human, PAM4 segment 350-362, amidated C-terminus, Fmoc-adducted N-terminus, synthetic, fibril type 2
| 350-362
| cryoEM
| 2.80
|  |
 |
8ohi
|
Louros et al., 2024
|
Tau
| Human, PAM4 segment 350-362, amidated C-terminus, Fmoc-adducted N-terminus, synthetic, fibril type 3
| 350-362
| cryoEM
| 2.70
|  |
 |
8ohp
|
Louros et al., 2024
|
Tau
| Human, PAM4 segment 350-362, amidated C-terminus, Fmoc-adducted N-terminus, synthetic, fibril type 4
| 350-362
| cryoEM
| 2.90
|  |
 |
8oi0
|
Louros et al., 2024
|
TDP-43
| Human, synthetic, residues 247-257
| 247-257
| cryoEM
| 3.7
|  |
 |
5w7v
|
Guenther et al., 2018
|
TDP-43
| Human, recombinant, residues 311-360
| 312-347
| cryoEM
| 3.8
|  |
 |
6n37
|
Cao et al., 2019
|
TDP-43
| Human, recombinant, residues 311-360
| 312-352
| cryoEM
| 3.8
|  |
 |
6n3b
|
Cao et al., 2019
|
TDP-43
| Human, recombinant, residues 311-360
| 311-360
| cryoEM
| 3.3
|  |
 |
6n3a
|
Cao et al., 2019
|
TDP-43
| Human, recombinant, A315E mutation, residues 286-331
| 288-319
| cryoEM
| 3.3
|  |
 |
6n3c
|
Cao et al., 2019
|
TDP-43
| Human, recombinant, Low Complexity Domain, residues 267-414
| 276-414
| cryoEM
| 3.2
|  |
 |
7kwz
|
Li et al., 2021
|
TDP-43
| Human, recombinant, full-length, morphology 1a
| 304-348
| cryoEM
| 3.76
|  |
 |
8qx9
|
Sharma et al., 2024
|
TDP-43
| Human, recombinant, full-length, morphology 1b
| 304-348
| cryoEM
| 4.05
|  |
 |
8qxa
|
Sharma et al., 2024
|
TDP-43
| Human, recombinant, full-length, morphology 2
| 304-348
| cryoEM
| 3.86
|  |
 |
8qxb
|
Sharma et al., 2024
|
TDP-43
| Human, extracted from Patient with Amyotrophic Lateral Sclerosis and Fronto-temporal Lobar Degeneration type B
| 282-360
| cryoEM
| 2.59
|  |
 |
7py2
|
Arseni et al., 2021
|
TDP-43 and Annexin A11
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration type C, variant 1
| 284-345, 39-74
| cryoEM
| 2.75
|  |
 |
9for
|
Arseni et al., 2024
|
TDP-43 and Annexin A11
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration type C, variant 2
| 282-345, 39-74
| cryoEM
| 2.90
|  |
 |
9fof
|
Arseni et al., 2024
|
TDP-43
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration type A, filament block variant 1
| 272-360
| cryoEM
| 2.39
|  |
 |
8cg3
|
Arseni et al., 2023
|
TDP-43
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration type A, filament block variant 2
| 281-360
| cryoEM
| 2.50
|  |
 |
8cgg
|
Arseni et al., 2023
|
TDP-43
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration type A, filament block variant 3
| 281-360
| cryoEM
| 2.68
|  |
 |
8cgh
|
Arseni et al., 2023
|
TDP-43
| Human, recombinant, residues 279-360 singlet fibril
| 281-351
| cryoEM
| 3.70
|  |
 |
7q3u
|
Kumar et al., 2023
|
TFG (237-327) G269V
| Recombinant, human, G269V mutation, low complexity domain (237-327)
| 262-290
| cryoEM
| 2.84
|  |
 |
8teq
|
Rosenberg et al., 2023
|
TFG (237-327) P285L
| Recombinant, human, P285L mutation, low complexity domain (237-327)
| 265-299
| cryoEM
| 2.59
|  |
 |
8ter
|
Rosenberg et al., 2023
|
TMEM106B
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration Type C, Polymorph 1
| 120-254
| cryoEM
| 2.90
|  |
 |
7saq
|
Jiang et al., 2022
|
TMEM106B
| Human, extracted from Patient with Alzheimer's Disease, case 1, Fold I
| 120-254
| cryoEM
| 2.64
|  |
 |
7qvc
|
Schweighauser et al., 2022
|
TMEM106B
| Human, extracted from Patient with Progressive Supranuclear Palsy, case 2, singlet filament
| 120-254
| cryoEM
| 3.00
|  |
 |
7u10
|
Chang et al., 2022
|
TMEM106B
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration Type A, case 1, singlet filament
| 120-254
| cryoEM
| 3.20
|  |
 |
7u11
|
Chang et al., 2022
|
TMEM106B
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration Type A, case 2, singlet filament
| 120-254
| cryoEM
| 3.50
|  |
 |
7u12
|
Chang et al., 2022
|
TMEM106B
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration Type A, case 4, singlet filament
| 120-254
| cryoEM
| 2.90
|  |
 |
7u13
|
Chang et al., 2022
|
TMEM106B
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration, Type C, case 8, singlet filament
| 120-254
| cryoEM
| 4.50
|  |
 |
7u14
|
Chang et al., 2022
|
TMEM106B
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration Type A, all cases combined, singlet filament
| 120-254
| cryoEM
| 2.70
|  |
 |
7u16
|
Chang et al., 2022
|
TMEM106B
| T185S mutation, human, extracted from Patient with Fronto-temporal Lobar Degeneration Type A, all cases combined, singlet filament
| 120-254
| cryoEM
| 2.70
|  |
 |
7u18
|
Chang et al., 2022
|
TMEM106B
| Human, extracted from brain of patient with Parkinsons Disease Dementia
| 120-254
| cryoEM
| 3.00
|  |
 |
7x84
|
Fan et al., 2022
|
TMEM106B
| Human, extracted from an individual with Amyltrophic Lateral Sclerosis/Parkinsonism-dementia complex (ALS/PDC), Guam case 1, fold I-s
| 120-254
| cryoEM
| 2.60
|  |
 |
8otd
|
Qi et al., 2023
|
TMEM106B
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration Type C, polymorph 2
| 120-254
| cryoEM
| 3.20
|  |
 |
7sar
|
Jiang et al., 2022
|
TMEM106B
| Human, extracted from Patient with Multiple System Atrophy, case 18, fold I-d
| 120-254
| cryoEM
| 3.64
|  |
 |
7qvf
|
Schweighauser et al., 2022
|
TMEM106B
| Human, extracted from an individual with Amyltrophic Lateral Sclerosis/Parkinsonism-dementia complex (ALS/PDC), Guam case 2, fold I-d
| 120-254
| cryoEM
| 3.60
|  |
 |
8ote
|
Qi et al., 2023
|
TMEM106B
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration Type C, polymorph 3
| 120-254
| cryoEM
| 3.70
|  |
 |
7sas
|
Jiang et al., 2022
|
TMEM106B
| Human, extracted from Patient with Multiple System Atrophy, case 19, Fold II-b
| 120-254
| cryoEM
| 3.47
|  |
 |
7qwl
|
Schweighauser et al., 2022
|
TMEM106B
| Human, extracted from Patient with Multiple System Atrophy, case 19, Fold II-a
| 120-254
| cryoEM
| 3.38
|  |
 |
7qwg
|
Schweighauser et al., 2022
|
TMEM106B
| Human, extracted from Patient with Fronto-temporal Lobar Degeneration Type B, case 7, singlet filament
| 120-254
| cryoEM
| 3.00
|  |
 |
7u15
|
Chang et al., 2022
|
TMEM106B T185S
| T185S mutation, human, extracted from Patient with Fronto-temporal Lobar Degeneration, Type B, all cases combined, singlet filament
| 120-254
| cryoEM
| 3.00
|  |
 |
7u17
|
Chang et al., 2022
|
TMEM106B
| Human, extracted from brain of 101 year old human with no diagnosed disease
| 120-254
| cryoEM
| 3.40
|  |
 |
7x83
|
Fan et al., 2022
|
TMEM106B
| Human, extracted from Patient with Multiple System Atrophy, case 17, Fold III
| 120-254
| cryoEM
| 2.76
|  |
 |
7qwm
|
Schweighauser et al., 2022
|
TMEM106B
| Human, extracted from a human centenarian, PBB3-bound
| 120-254
| cryoEM
| 3.00
|  |
 |
8j7n
|
Zhao et al., 2024
|
TMEM106B
| Human, extracted from a centenarian, PiB-bound
| 120-254
| cryoEM
| 3.40
|  |
 |
8j7p
|
Zhao et al., 2024
|
Transforming Growth Factor Beta Induced Protein, TGFBIp(611-633), G623R
| Human, recombinant
| 1-23
| cryoEM
| 4.90
|  |
 |
8hia
|
Low et al., 2023
|
Transthyretin, V30M
| Human, V30M mutation, extracted from the Vitreous Body of the Eye of an Amyloid Transthyretin Amyloidosis (ATTR) Patient
| 11-35, 57-123
| cryoEM
| 3.22
|  |
 |
7ob4
|
Iakovleva et al., 2021
|
Transthyretin, V30M
|
Human, V30M mutation, extracted from heart of a patient with hereditary V30M ATTR Amyloidosis
|
11-35, 57-123
|
cryoEM
|
3.0
|
 |
 |
6sdz
|
Schmidt et al., 2019
|
Transthyretin
| Human, wild type, extracted from the heart a Senile Systemic Amyloidosis Patient
| 11-35, 57-123
| cryoEM
| 2.78
|  |
 |
8ade
|
Steinebrei et al., 2022
|
Transthyretin
| Human, wild type, extracted from the heart a Senile Systemic Amyloidosis Patient
| 11-35, 57-123
| cryoEM
| 2.78
|  |
 |
7z40
|
Steinebrei et al., 2022
|
Transthyretin
| Human, wild type, extracted from the heart a Transthyretin Amyloidosis Patient
| 11-35, 57-124
| cryoEM
| 3.40
|  |
 |
8gbr
|
Nguyen et al., 2024 Biorxiv
|
Transthyretin
| Human, wild type, extracted from the heart a Transthyretin Amyloidosis Patient
| 11-34, 58-123
| cryoEM
| 3.31
|  |
 |
8e7d
|
Nguyen et al., 2023 Biorxiv
|
Transthyretin
| Human, wild type, extracted from the heart a Transthyretin Amyloidosis Patient
| 11-35, 58-123
| cryoEM
| 3.28
|  |
 |
8g9r
|
Nguyen et al., 2024 Biorxiv
|
Transthyretin
| Human, wild type, extracted from the heart a Transthyretin Amyloidosis Patient
| 12-35, 58-123
| cryoEM
| 3.70
|  |
 |
8e7h
|
Nguyen et al., 2023 Biorxiv
|
Transthyretin, P24S
| Human, P24S mutation, extracted from the heart a Transthyretin Amyloidosis Patient
| 12-34, 58-123
| cryoEM
| 3.65
|  |
 |
8e7i
|
Nguyen et al., 2023 Biorxiv
|
Transthyretin, I84S
| Human, I84S mutation, extracted from the heart a Transthyretin Amyloidosis Patient, Closed Gate conformation
| 11-35, 57-124
| cryoEM
| 3.10
|  |
 |
8tdn
|
Nguyen et al., 2024
|
Transthyretin, I84S
| Human, I84S mutation, extracted from the heart a Transthyretin Amyloidosis Patient, Open Gate conformation
| 10-36, 59-124
| cryoEM
| 3.10
|  |
 |
8tdo
|
Nguyen et al., 2024
|
Transthyretin, I84S
| Human, I84S mutation, extracted from the heart a Transthyretin Amyloidosis Patient, Broken Gate conformation
| 12-35, 64-122
| cryoEM
| 3.10
|  |
 |
8e7j
|
Nguyen et al., 2024
|
Transthyretin, I84S
| Human, I84S mutation, extracted from the heart a Transthyretin Amyloidosis Patient, Absent Gate conformation
| 14-32, 67-122
| cryoEM
| 3.61
|  |
 |
8e7e
|
Nguyen et al., 2024
|
